Hypertensive crisis resident survival guide

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ayokunle Olubaniyi, M.B,B.S [2]

Definitions

  • Hypertensive urgencies - These are severe elevations in blood pressure with no or minimal evidence of target organ damage.[1] An example is a blood pressure of greater than 160/100 mmHg (stage 2 hypertension) associated with severe headache, shortness of breath, nosebleeds, or severe anxiety.
  • Hypertensive emergencies - These are severe elevations in blood pressure, usually greater than 180/120 mmHg, complicated by evidence of impending or progressive target organ dysfunction. They warrant urgent blood pressure reduction by parenteral agents to prevent or limit target organ damage.[1] This is a clinical diagnosis. Examples include: hypertensive encephalopathy, intracerebral hemorrhage, acute myocardial infarction, e.t.c.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

  • All the causes of hypertensive emergencies are life-threatening.

Common Causes

Management

 
 
 
 
Characterize the symptoms:
❑ CNS - severe headache, dizziness, confusion, weakness/numbness, altered/LOC, difficulty speaking
❑ Eyes - pain, blurred/loss of vision
❑ Cardiopulmonary - chest pain, dyspnea
❑ Renal - hematuria, proteinuria, reduced urinary output
❑ Others - nausea/vomiting, severe anxiety, nosebleeds
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluate the patient:
❑ History
PMH especially HTN
Medications - dosages, compliance
Recreational drug use - methamphetamine, cocaine, phencyclidine
❑ Physical
Blood pessure - both arms
Fundoscopy - papilledema, exudates, hemorrhages
Neuro exam - mental status, focal neurological deficits
Cardiopulmonary - signs of pulmonary edema
Abdomen - pulsatile masses, tenderness, bruits
Limbs - peripheral pulses
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Order Labs:
❑ CBC
❑ BMP + Mg + PO4
❑ Serum uric acid
❑ FLP
❑ FBS
❑ Urinalysis/culture
❑ Urine electrolytes, creatinine, protein
❑ Chest X-ray
❑ EKG, ECHO
❑ Renal USS + doppler
 
Further work-up:
❑ TSH, free T3, free T4
❑ Serum cortisol
❑ Serum aldosterone
❑ Serum renin levels
❑ HbA1C
❑ 24-hr urinary catecholamine & metanephrine levels
❑ Serum parathyroid hormone levels
❑ Urine and serum toxicology screen
❑ Urine pregnancy test
❑ CT/MRI
❑ DMSA/DTPA scans (renal scars)
❑ ANA/ESR/CRP/anti-dsDNA/anti-smith/rheumatoid factor/p-ANCA/c-ANCA
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evidence of end organ damage (any of the symptoms above)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YES
 
 
 
 
 
NO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hypertensive emergency
(NB - Treat the patient and not the BP)
 
 
 
 
 
Hypertensive urgency
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Admit ICU[2]
Close BP monitoring

Intra-arterial BP monitoring in severely-ill patients

Assess volume status - IV N/S if volume depleted to prevent precipitous fall in BP following administration of antihypertensives

Commence IV antihypertensives based on patient's symptom

Change IV meds to oral when BP is stable
NB - Not more than 25% reduction in BP within the 1st hour; when BP is stable, reduce to 160/100-110 mmHg within the next 2-6 hours
 
 
 
 
 
 
Outpatient/Admit for observation
Oral antihypertensives
Clinical surveillance within the first few hours of commencing medications
NB - Gradual BP reduction over 24 - 48 hours
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Management of specific hypertensive emergencies
 
 
 
 
Worsening blood pressure
 
Good control
Review old/start new medication
Modify risk factors
Close follow-up
 
 
 

Intravenous Antihypertensives

Drug Dose Onset of action Duration of action Special indication Avoid use
Clevidipine 1 to 2 mg/h as IV infusion, max 16 mg/h 2-4 mins 5-15 mins Most HE -----
Enalaprilat 1.25–5 mg every 6 hrs IV 15–30 6–12 hrs Acute left ventricular failure AMI, renal impairment, pregnancy. No benefit in HE.
Fenoldopam 0.1–0.3 µg/kg per min IV infusion <5 min 30 min Most HE + renal insufficiency Glaucoma or ↑ICP
Hydralazine 10–20 mg IV 10–20 min IV 1–4 hrs Eclampsia; although labetalol or nicardipine is preferred This should generally be avoided due to its unpredictable pharmacodynamics
Nicardipine 5–15 mg/h IV 5–10 min 1.5 - ≥4 hrs Most HE esp post-op hypertension, aortic dissection & pregnancy Acute heart failure. Caution with cirrhotics & coronary ischemia
Nitroglycerin 5–100 µg/min as IV infusion 2–5 min 5–10 min Coronary ischemia, cardiogenic pulmonary edema Not used for most HE
Nitroprusside 0.25–10 µg/kg/min as IV infusion Immediate 1–2 min Most HE; should be avoided due to its toxicity (cyanide toxicity) Caution with ↑ICP, AMI, CAD, CVA, renal or hepatic impairment.
Esmolol 250–500 µg/kg/min IV bolus, then 50–100 µg/kg/min by infusion; may repeat bolus after 5 min or increase infusion to 300 µg/min 1–2 min 10–30 min Aortic dissection, perioperative (to reduce reflex tachycardia) Acute decompensated heart failure
Labetalol 20–80 mg IV bolus every 10 min 0.5–2.0 mg/min IV infusion 5–10 min 3–6 hrs Most HE; used in combination with vasodilators to reduces reflex tachycardia Acute decompensated heart failure, heart block, asthma, pheochromocytoma
Phentolamine 5–15 mg IV bolus 1–2 min 10–30 min Catecholamine excess
  • HE - Hypertensive emergencies

Oral Antihypertensives

Drug Dose Onset of action Duration of action
Captopril 12.5 to 25 mg PO or SL, repeat as needed. max dose - 50 mg PO 5-15 mins 2-6 hrs
Clonidine 0.1-0.2 mg PO x 1, then 0.05 to 0.1 mg/1-2 hrs. Max dose - 0.6 to 0.7 mg 15-30 mins 2-8 hrs
Labetalol 200 mg PO, then 200 mg/hr until desired effect. Max dose - 1200 mg 2 hrs 4 hrs
  • Other agents to consider include:
  1. PO frusemide 20mg (repeat as necessary)
  2. PO nifedipine SR 30mg, single dose
  3. PO felodipine 5 mg, single dose

Management of Specific Hypertensive Emergencies

Hypertensive emergencies Preferred agents Note
Aortic dissection Labetalol, nicardipine + esmolol, nitroprusside + esmolol or IV metoprolol Administer beta blocker to control the heart rate before initiating a vasodilator e.g. nitroprusside
  • Reduce BP to 120 mmHg within 20 minutes with protection against reflex tachycardia.[1]
Acute pulmonary edema/systolic dysfunction NTG + (Nicardipine, fenoldopam, or nitroprusside) + loop diuretic
Acute pulmonary edema/diastolic dysfunction Low-dose NTG + (esmolol, metoprolol, labetalol, or verapamil) + loop diuretic
Acute coronary syndrome NTG + (labetalol or esmolol)
Hypertensive emergency with ARF/CRF Nicardipine or fenoldopam
Hypertensive encephalopathy Nicardipine, labetalol, fenoldopam (if renally impaired), clevidipine, nitroprusside (only if necessary) The BP should not be lowered by more than 25%
Pre-eclampsia/eclampsia Labetalol or nicardipine
Sympathetic crisis/cocaine overdose Benzodiazepine + (verapamil, diltiazem, or nicardipine); phentolamine or nitroprusside Beta blockers should NOT be administered alone to prevent un-opposed alpha-adrenergic stimulation
Cerebrovascular accident Nicardipine, labetalol, fenoldopam, or clevidipine An expert's judgement is required to determine if the BP should be lowered.
Withdrawal of antihypertensive therapy e.g. clonidine or propanolol Re-administer the discontinued drug; phentolamine, nitroprusside, or labetalol, if necessary

Dos

  • Hypertensive emergencies are best managed with a continuous infusion of short-acting titratable antihypertensive agents.
  • Both sublingual and intramuscular routes of drug administration should be avoided due to their unpredictable pharmacodynamics.
  • Assess patients' volume status before commencing intravenous vasodilators to prevent/minimize precipitous fall in blood pressure.[3]

Don'ts

References

  1. 1.0 1.1 1.2 Chobanian, AV.; Bakris, GL.; Black, HR.; Cushman, WC.; Green, LA.; Izzo, JL.; Jones, DW.; Materson, BJ.; Oparil, S. (2003). "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report". JAMA. 289 (19): 2560–72. doi:10.1001/jama.289.19.2560. PMID 12748199. Unknown parameter |month= ignored (help)
  2. 2.0 2.1 Varon, J. (2008). "Treatment of acute severe hypertension: current and newer agents". Drugs. 68 (3): 283–97. PMID 18257607.
  3. Marik, PE.; Varon, J. (2007). "Hypertensive crises: challenges and management". Chest. 131 (6): 1949–62. doi:10.1378/chest.06-2490. PMID 17565029. Unknown parameter |month= ignored (help)

Template:WH Template:WS